Effect of sublingual Vitamin D3 on chronic kidney disease.
Abstract
The present study was aimed to study the effect of Sublingual Vitamin D3 on Chronic Kidney Disease. This was a non-randomized clinical trial and interventional study. Total of 400 patients were enrolled for the study. All the subjects were screened for the serum 25(OH)D level. Subjects fulfilling the eligibility criteria with serum 25(OH)D level less than 20 ng/ml, having history of renal dysfunction were included in the study. At the end of the study, 49 patients (24 from Test and 25 from control group) dropped out of the study due to their personal reasons and finally 351 patients participated till the end of the study,176 patients in test group and 175 in control group. There was statistically significant difference in serum vitamin D3 level before 16.61±6.71 ng/ml and after 35.80±7.80 ng/ml after treatment with Sublingual Vitamin D3, whereas in the control group decreased from baseline 16.40±3.63ng/ml to 14.96±4.94 ng/ml. As per the information is taken from the patients, 38 participants in the test group (21.59%) and 41 in the control group (23.42%) had a history of renal dysfunction in our study. In our study there were no significant changes in the Renal Function Test on giving sublingual vitamin D3 further multicentred trials with large sample size are required to come to a conclusion. However, improvement in hypertension as a result of vitamin D3 could prove effective in treating CKD. further multicentred trials with large sample size are required to come to a conclusion.
Downloads
References
Veerappan I, Abraham G. Chapter 130. Chronic Kidney Disease: Current Status, Challenges, and Management in India. The Association of Physicians in India –Medicine Update 2013;593-597.
Ene-Iordache B et al. Lancet Glob Health 2016;4: e307-19.
Braun LA, Sood V, Hogue S, et al. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis 2012; 5:151–163.
Eckardt KU, Coresh J, Devuyst O, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382:158–69.
Singh AK, Farag YM, Mittal BV, et al. Epidemiology and risk factors of chronic kidney disease in India – results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMCNephrology 2013; 14:114.
Johnson CA, Levey AS, Coresh J, et al. Clinical Practice Guidelines for Chronic Kidney Disease in Adults: Part I. Definition, Disease Stages, Evaluation, Treatment, and Risk Factors. Am FamPhysician 2004; 70:869-76.
Davies DF, Shock NW. Age changes in glomerular filtration rate (ERPS) and tubular resorption capacity in adult males. J Clin Invest 1950; 29:496-507.
Riggs BL, Hanstra A, DeLuca HS. Assessment of 25-hydroxyvitamin D 1ahydroxylates reserved in postmenopausal osteoporosis by the administration of parathyroid extracts. J Clin EndocrinolMetab198 l; 53:833-5.
Charumathi Sabanayagam, Anoop Shankar,Shanmugasundaram Somasundaram.Serum Vitamin D Level and Prehypertension among Subjects Free of Hypertension. Kidney Blood Press Res 2012; 35:106–113.
Haussler MR, Donaldson CA, Kelly MA, et al: Functions and mechanism of action of the 1,25dihydroxyvitaminD3 receptor, in Norman AW: Vitamin D. A Chemical, Biochemical and Clinical Update. Berlin, Walter de Gruyter & Co, 1985, pp 83-92.
Levin, A.; Bakris, G.L.; Molitch, M.; Smulders, M.; Tian, J.; Williams, L.A.; Andress, D.L. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int. 2007, 71, 31–38.
Dusso, A.; Gonzalez, E.A.; Martin, K.J. Vitamin d in chronic kidney disease. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25, 647–655. Nutrients 2013, 5
Moe, S.; Drueke, T.; Cunningham, J.; Goodman, W.; Martin, K.; Olgaard, K.; Ott, S.; Sprague, S.; Lameire, N.; Eknoyan, G. Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (kdigo).Kidney Int. 2006, 69, 1945–1953.
Andress, D.L. Vitamin D in chronic kidney disease: A systemic role for selective vitamin d receptor activation. Kidney Int. 2006, 69, 33–43.96.
Jacob, A.I.; Sallman, A.; Santiz, Z.; Hollis, B.W. Defective photoproduction of cholecalciferol in normal and uremic humans. J. Nutr. 1984, 114, 1313–1319.
De Boer, I.H.; Ioannou, G.N.; Kestenbaum, B.; Brunzell, J.D.; Weiss, N.S. 25- hydroxyvitamin D levels and albuminuria in the third national health and nutrition examination survey (NHANES iii). Am. J. Kidney Dis. 2007, 50, 69–77.
Wei Ren Chen ,Zhi Ying Liu , Yang Shi , Da Wei Yin , Hao Wang , Yuan Sha ,Yun Dai Chen.Vitamin D and nifedipine in the treatment of Chinese patients with
grades I- II essential hypertension: A randomized placebo-controlled trial. Atherosclerosis.2014;235:102-109.
Hamid Nasri, Saeed Behradmanesh, Ali Ahmadi, Mahmoud RafieianKopaei.Impact of oral vitamin D (cholecalciferol) replacement therapy on blood pressure in type 2 diabetes patients; a randomized, double-blind, placebo-controlled clinical trial. J Nephropathol.2014; 3(1): 29-33.
M. D. Witham, F. J. Dove, M. Dryburgh J. A. Sugden & A. D. Morris & A. D. Struthers. The effect of different doses of vitamin D3 on markers of vascular health
in patients with type 2 diabetes: a randomized controlled trial.2010;2:1-8.
Davies DF, Shock NW. Age changes in glomerular filtration rate (ERPS) and tubular resorption capacity in adult males. J Clin Invest.1950; 29:496-507.
Riggs BL, Hamstra A, DeLuca HS. Assessment of 25-hydroxyvitamin D 1ahydroxylates reserved in postmenopausal osteoporosis by administration of parathyroid extracts. J Clin Endocrinol Metab.198l; 53:833-5.
Helvig, C.F., Cuerrier, D., Hosfield, C.M. et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney International.2010; 78:463–472.
A Triantafyllou, S Douma1, K Petidis, M Doumas, E Panagopoulou, S Tsotoulidis, C Zamboulis. Prevalence, awareness, treatment and control of hypertension in
an elderly population in GreeceTIEJRRHREPP;2010:1-10.
Aris D. Efstratopoulos, Sofia M. Voyaki, Athanasios A. Baltas, Filippos A. Vratsistas, Dimitrios-Eteoklis P. Kirlas, John T. Kontoyannis, John G. Sakellariou, George B. Triantaphyllou, Gregorios A. Alokrios, Dimitrios N. Lianas, Emanuel A. Vasilakis, Kyriakos N. Fotiadis, and Evangelia E. Kastritsea, Prevalence, Awareness, Treatment
and control of Hypertension in Hellas, Greece AJH .2006; 19:53–60.
Angela Yee-Moon Wang, Fang Fang,† John Chan, Yue-Yi Wen, Shang Qing, Iris HiuShuen Chan, Gladys Lo, Kar-Neng Lai, Wai-Kei Lo, Christopher Wai-Kei Lam, Cheuk-Man Yu. Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial. J Am Soc Nephrol.2014;25: 175–186.
Michael Pfeifer, Bettina Begerow, Helmut W. Minne, Detlef Nachtigall, And Corinna Hansen.Effects of a Short-Term Vitamin D3 and Calcium Supplementation on Blood Pressure and Parathyroid Hormone Levels in Elderly Women. J Clin Endocrinol Metab 2001:86: 1633–1637.
Davide Carrara, Matteo Bernini, Alessandra Bacca, Ilaria Rugani, Emiliano Duranti, Agostino Virdis, et al. Cholecalciferol administration blunts the systemic renin–angiotensin system in essential hypertensives with hypovitaminosis D. Journal of the Renin-AngiotensinAldosterone System. 2012; 0: 1–6.
Angela Yee-Moon Wang, Fang Fang,† John Chan, Yue-Yi Wen, Shang Qing,Iris HiuShuen Chan, Gladys Lo, Kar-Neng Lai, Wai-Kei Lo,Christopher Wai-KeiLam,Cheuk-Man Yu. Effect of Paricalcitol on Left Ventricular Mass and Function in CKD—The OPERA Trial. J Am Soc Nephrol.2014;25: 175–186.
Youssef Khalel Ahmad, Esam Mohamed El-Ghamry, Salwa Tawfik, Wael Mohamed Atia, Mohammad Mohammad Keder, Sameh Ahmad Abd-El Kader.
Assessment of Vitamin D Status in Patients with Essential Hypertension. The Egyptian Journal of Hospital Medicine.2018;72 (5):4434-4438.
